BiotechTube

AU-011

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Eye Cancer

Conditions

Eye Cancer, Primary Cancer

Trial Timeline

Dec 16, 2024 → Oct 31, 2027

NCT ID
NCT06643884

About AU-011

AU-011 is a phase 2 stage product being developed by Aura Biosciences for Eye Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06643884. Target conditions include Eye Cancer, Primary Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (4)

NCT IDPhaseStatus
NCT06643884Phase 2Recruiting
NCT05483868Phase 1Recruiting
NCT05266430Pre-clinicalTerminated
NCT04417530Phase 2Completed

Competing Products

20 competing products in Eye Cancer

See all competitors
ProductCompanyStageHype Score
E7389EisaiPhase 1
33
VeliparibAbbViePhase 2
52
AK-105AkesoPhase 1
32
XL820ExelixisPhase 1
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
LY3300054 + PrexasertibEli LillyPhase 1
33
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
NBTXR3NanobiotixPhase 1/2
36

Other Products from Aura Biosciences

Bel-sarPhase 3
69
AU-011Phase 2
44
Light-activated AU-011Phase 1/2
33
AU-011Phase 1
25
AU-011Pre-clinical
15